INmune Bio Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for INmune Bio, Inc. (INMB) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-42.08-30.00-27.30-30.34-12.10-7.68
Depreciation & Amortization0.000.000.240.130.000.00
Stock Based Compensation7.617.377.154.803.110.00
Change in Working Capital1.0410.44-2.86-0.18-0.16-0.19
Change in Accounts Receivable1.030.000.000.000.000.00
Change in Accounts Payable-1.372.721.402.261.080.00
Change in Other Working Capital0.087.720.240.13-1.030.00
Other Operating Activities0.080.220.241.893.322.48
Net Cash from Operating Activities-33.36-12.00-22.69-28.50-8.94-5.38
Investing Activities
Capital Expenditures0.000.000.0015.000.000.00
Sales/Maturities of Investments0.000.000.00-15.000.000.00
Other Investing Activities0.000.000.00-15.000.000.00
Net Cash from Investing Activities0.000.000.00-15.000.000.00
Financing Activities
Debt Repayment-10.00-5.000.000.000.000.00
Common Stock Issued27.790.780.7080.2524.9112.21
Common Stock Repurchased0.000.000.000.00-1.010.00
Other Financing Activities0.420.000.000.00-1.010.00
Net Cash from Financing Activities18.21-4.230.7396.3623.9012.21
Summary
Effect of Forex Changes on Cash0.22-0.10-0.70-0.010.02-0.02
Net Change in Cash-15.15-16.31-21.9652.8414.976.82
Cash at Beginning of Period35.8552.1574.8121.977.000.19
Cash at End of Period20.92-30.0052.1574.8121.977.00
Free Cash Flow-33.36-12.00-22.69-43.50-8.94-5.38
Supplemental Disclosures
Interest Paid1.691.781.370.560.000.00